Clinical Trials Logo

Clinical Trial Summary

Large amounts of experimental and animal evidence have confirmed that iron accumulation is associated with bone loss. However, it is still lack of the clinical studies relating iron accumulation to bone loss, especially in the pathological conditions during our Chinese. In this study, the investigators aim to assess the association between the levels of serum ferritin and bone mineral density in Chinese healthy postmenopausal women.


Clinical Trial Description

For the past few years, an increasing number of in vitro studies show the association of iron accumulation with bone loss, particularly in postmenopausal women. And body iron accumulation is accurately reflected by levels of serum ferritin in clinic. The levels of serum ferritin among healthy women are about 13-150μg/L, and we give a definition of iron accumulation when serum ferritin range from 500μg/L to 1000 μg/L. How will the bone mineral density change in iron accumulation? The investigators intend to perform this study to explore and establish the relational function and logical function between serum ferritin, bone mineral density and biochemical markers of bone metabolism in Chinese healthy postmenopausal women. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03512743
Study type Observational
Source Second Affiliated Hospital of Soochow University
Contact
Status Enrolling by invitation
Phase
Start date May 1, 2018
Completion date June 1, 2019

See also
  Status Clinical Trial Phase
Completed NCT01544894 - Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis Phase 4
Completed NCT00529373 - A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018) Phase 3
Completed NCT00377819 - Study of Transitioning From Alendronate to Denosumab Phase 3
Completed NCT00381251 - Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation. Phase 1
Completed NCT00239629 - Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial Phase 4
Completed NCT00092014 - A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211) Phase 3
Recruiting NCT02981732 - CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome N/A
Completed NCT01657162 - Twenty Four Month Extension Study of BA058-05-003 Phase 3
Completed NCT01709110 - VERtebral Fracture Treatment Comparisons in Osteoporotic Women Phase 4
Completed NCT01348243 - Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis Phase 3
Completed NCT00541658 - A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis Phase 3
Completed NCT00395395 - Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women Phase 1
Completed NCT00247273 - A Study of Monthly Risedronate for Osteoporosis Phase 3
Completed NCT01668589 - Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis N/A
Completed NCT01221727 - The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam Phase 1
Completed NCT00996801 - MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012) Phase 2
Completed NCT00909961 - A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years Phase 3
Completed NCT00079924 - Effects of Teriparatide in Postmenopausal Women With Osteoporosis Phase 4
Completed NCT02157948 - A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis Phase 3
Withdrawn NCT01552122 - Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050) Phase 3